Biodegradable microspheres of novel segmented poly(ether-ester-amide)s based on poly(ε-caprolactone) for the delivery of bioactive compounds

被引:70
作者
Barbato, F
La Rotonda, MI
Maglio, G
Palumbo, R
Quaglia, F
机构
[1] Univ Naples, Dipartimento Chim Farmaceut & Tossicol, Naples, Italy
[2] Univ Naples, Dipartimento Chim, Naples, Italy
关键词
poly(ether-ester-amide)s; poly(epsilon-caprolactone); biodegradable polymers; microspheres; controlled release;
D O I
10.1016/S0142-9612(00)00291-X
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
A novel class of multiblock poly(epsilon -caprolactone)-based polymers containing hydrophilic trioxyethylene segments and potentially relevant to the delivery of drugs is described in this work. L-phenylalanine residues mag; also be inserted into the hydrophilic blocks to generate peptide bonds susceptible to enzymatic attack. The investigated polymers mere poly(ether-ester-amide)s (PEEAs) obtained by a two-step polymerization procedure from OH- end capped low molecular weight poly(epsilon -caprolactone), sebacoyl chloride and either 4,7,10-trioxa - 1,13-tridecanediamine (PEEA1) or 1,13-di(L-phenylalaninamido)-3,7,10-trioxatridecane (PEEA2). PEEAs were characterized by H-1-NMR spectroscopy, differential scanning calorimetry, gel permeation chromatography and were tested for their suitability in producing microspheres. Particles obtained by the single emulsion-solvent evaporation technique were regular and smooth (SEM analysis) showing a monomodal distribution of dimensions. To assess the potentiality of PEEAs in the oral delivery of drugs, three model compounds with different pK(a) and solubilities - diclofenac, nicardipine and dicumarol - were encapsulated within PEEA microspheres. For the sake of comparison, microspheres prepared from poly(epsilon -caprolactone) (PCL) with a molecular weight similar to PEEAs: were also prepared and tested. The release of diclofenac from all the microspheres was very rapid (100% released within 1h) whereas nicardipine release was slower and biphasic. The initial phase approximated a near zero-order release, being the fraction of nicardipine released after X h from PEEA microspheres higher with respect to PCL particles (about 70 vs. 30%). This result was ascribed to the lower crystallinity of PEEAs with respect to PCL which results in a facilitated access of water molecules through the polymer matrix. The lipophilic-unionizable dicumarol was released from PEEA microspheres at a very slow rate. Therefore, dicumarol-loaded PEEA microspheres allowed the study of the influence on the release rate of the insertion into the polymer chain of enzymatically degradable bonds. PEEA2 microspheres released dicumarol at the same rate in a medium with or without the proteolitic enzyme alpha -chymotrypsin. Although the insertion of an isolated amino acid was not sufficient to confer enzyme susceptibility to the polymer, the distinctive properties of PEEAs make their use very attractive in the field of controlled release. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1371 / 1378
页数:8
相关论文
共 16 条
[1]  
BENOIT JP, 1996, MICROENCAPSULATION M, P35
[2]   Biocompatible alpha-aminoacids based aliphatic polyamides [J].
Bianco, B ;
Castaldo, L ;
delGaudio, A ;
Maglio, G ;
Palumbo, R ;
LaCara, F ;
Peluso, G ;
Petillo, O .
POLYMER BULLETIN, 1997, 39 (03) :279-286
[4]   The application of microspheres from the copolymers of lactide and ε-caprolactone to the controlled release of steroids [J].
Buntner, B ;
Nowak, M ;
Kasperczyk, J ;
Ryba, M ;
Grieb, P ;
Walski, M ;
Dobrzyñski, P ;
Bero, M .
JOURNAL OF CONTROLLED RELEASE, 1998, 56 (1-3) :159-167
[5]   THE ACCELERATION OF DEGRADATION-CONTROLLED DRUG DELIVERY FROM POLYESTER MICROSPHERES [J].
CHA, Y ;
PITT, CG .
JOURNAL OF CONTROLLED RELEASE, 1989, 8 (03) :259-265
[6]  
DOMB AJ, 1994, POLYM BIOMATERIALS, P339
[7]  
HUANG SJ, 1979, J APPL POLYM SCI, V23, P429, DOI 10.1002/app.1979.070230212
[8]  
Jenkins V. F., 1977, POLYM PAINT COLOUR J, V167, P622
[9]  
KOLESKE JV, 1978, POLYM BLENDS, V2, P369
[10]  
Lewis D.H., 1990, Biodegradable polymers as drug delivery systems, P1